We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+14.39%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.85B
AUM Growth
+$177M
Cap. Flow
-$53.9M
Cap. Flow %
-1.89%
Top 10 Hldgs %
28.19%
Holding
216
New
12
Increased
42
Reduced
44
Closed
16

Top Buys

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$46M
2
DHR icon
Danaher
DHR
+$34.4M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$30.2M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$22.3M
5
DXCM icon
DexCom
DXCM
+$20M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$44.2M
2
MRK icon
Merck
MRK
+$39.7M
3
PFE icon
Pfizer
PFE
+$39.7M
4
ABBV icon
AbbVie
ABBV
+$24.5M
5
CNC icon
Centene
CNC
+$23.8M

Sector Composition

Rank Sector Weight
1 Healthcare 95.34%
2 Real Estate 2.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGIO icon
201
Agios Pharmaceuticals
AGIO
$1.89B
– –
-186,964
Closed -$6.54M
BAX icon
202
Baxter International
BAX
$14.7B
– –
-122,023
Closed -$9.81M
BLUE
203
DELISTED
bluebird bio
BLUE
– –
-6,500
Closed -$4.54M
BNTX icon
204
BioNTech
BNTX
$23.1B
– –
-43,595
Closed -$3.02M
CHRS icon
205
Coherus Oncology
CHRS
$228M
– –
-203,103
Closed -$3.73M
COR icon
206
Cencora
COR
$59.6B
– –
-80,645
Closed -$7.82M
LKFT
207
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.73B
– –
-6,543
Closed -$929K
GSK icon
208
GSK
GSK
$103B
– –
-25,920
Closed -$1.22M
TCDA
209
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-50,370
Closed -$456K
GBT
210
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-71,759
Closed -$3.96M
CERN
211
DELISTED
Cerner Corp
CERN
– –
-81,500
Closed -$5.89M
MYOK
212
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-19,300
Closed -$2.63M
IMMU
213
DELISTED
Immunomedics Inc
IMMU
– –
-223,336
Closed -$19M
MNK
214
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
– –
-32,980
Closed -$32K
BHVN
215
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-34,277
Closed -$2.23M
5 6 7 8
9

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Tekla Capital Management held 216 positions worth $2.85B, up 6.6% from $2.67B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Tekla Capital Management's Q4 2020 filing shows 12 new, 42 increased, 44 reduced and 16 closed positions. Its largest new stake was Teladoc Health: 56,520 shares worth $11.3M. The largest sale was Amgen, an estimated $44.2M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q4 2020 buy was Teladoc Health: 56,520 shares worth $11.3M.
  • Tekla Capital Management added most to Thermo Fisher Scientific in Q4 2020, an estimated $46M increase.
  • Tekla Capital Management's biggest Q4 2020 reduction was Amgen, cutting an estimated $44.2M.
  • Tekla Capital Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $19M.
  • Tekla Capital Management's ten largest holdings make up 28% of its $2.85B portfolio in Q4 2020.
  • Tekla Capital Management opened 12 new positions and closed 16 in Q4 2020.
  • Tekla Capital Management's portfolio value rose 6.6% quarter-over-quarter to $2.85B.

Based on Tekla Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.